Pablo Borrega

774 total citations
28 papers, 243 citations indexed

About

Pablo Borrega is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Pablo Borrega has authored 28 papers receiving a total of 243 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 9 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Pablo Borrega's work include Prostate Cancer Treatment and Research (11 papers), Radiopharmaceutical Chemistry and Applications (8 papers) and Cancer Treatment and Pharmacology (6 papers). Pablo Borrega is often cited by papers focused on Prostate Cancer Treatment and Research (11 papers), Radiopharmaceutical Chemistry and Applications (8 papers) and Cancer Treatment and Pharmacology (6 papers). Pablo Borrega collaborates with scholars based in Spain, United States and France. Pablo Borrega's co-authors include Yolanda Escobar, Juan Antonio Virizuela, Enrique Espinosa, Javier Cassinello, Javier de Castro, Jaime Feliú, Angelo Gámez‐Pozo, Iker Sánchez‐Navarro, Luis Antón-Aparicio and R. Pérez-Carrión and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Pablo Borrega

24 papers receiving 237 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Pablo Borrega Spain 8 116 93 93 72 30 28 243
Samira El Bouazzaoui Netherlands 10 71 0.6× 159 1.7× 46 0.5× 77 1.1× 37 1.2× 17 321
Paula Jiménez Fonseca Spain 11 78 0.7× 147 1.6× 43 0.5× 94 1.3× 13 0.4× 24 310
Dan Moldoveanu Canada 8 43 0.4× 77 0.8× 50 0.5× 67 0.9× 39 1.3× 17 271
Fiona Langlands United Kingdom 7 56 0.5× 91 1.0× 83 0.9× 70 1.0× 10 0.3× 11 250
Nur Sabrina Sapari Singapore 7 48 0.4× 67 0.7× 52 0.6× 110 1.5× 7 0.2× 15 199
Natalie Reizine United States 9 162 1.4× 173 1.9× 48 0.5× 32 0.4× 5 0.2× 27 315
Zafer Cantürk Türkiye 9 102 0.9× 105 1.1× 87 0.9× 41 0.6× 3 0.1× 17 260
Krystyna Reczko United Kingdom 6 40 0.3× 76 0.8× 55 0.6× 19 0.3× 7 0.2× 10 188
Shubao Wang China 11 219 1.9× 64 0.7× 33 0.4× 64 0.9× 9 0.3× 36 357
J. R. J. Elbers Netherlands 9 165 1.4× 96 1.0× 50 0.5× 56 0.8× 6 0.2× 11 362

Countries citing papers authored by Pablo Borrega

Since Specialization
Citations

This map shows the geographic impact of Pablo Borrega's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pablo Borrega with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pablo Borrega more than expected).

Fields of papers citing papers by Pablo Borrega

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pablo Borrega. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pablo Borrega. The network helps show where Pablo Borrega may publish in the future.

Co-authorship network of co-authors of Pablo Borrega

This figure shows the co-authorship network connecting the top 25 collaborators of Pablo Borrega. A scholar is included among the top collaborators of Pablo Borrega based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pablo Borrega. Pablo Borrega is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
García-Donás, Jesús, Guillermo de Velasco, Rodrigo Madurga, et al.. (2023). Case–control study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study. Clinical & Translational Oncology. 26(3). 732–738. 1 indexed citations
4.
Escobar, Yolanda, Avinash Ramchandani, Mercedes Salgado, et al.. (2023). What do patients and oncologists think about the evaluation and management of cancer-related anorexia-cachexia? The Quasar_SEOM study. Clinical & Translational Oncology. 25(12). 3479–3491. 1 indexed citations
5.
Carles, Joan, Teresa Alonso‐Gordoa, Begoña Mellado, et al.. (2022). Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial. European Journal of Cancer. 173. 317–326. 7 indexed citations
6.
Delanoy, Nicolas, Antoine Angelergues, Eleni Efstathiou, et al.. (2017). Sequencing in metastatic castration-resistant prostate cancer (mCRPC): Updated results of the FLAC International Database.. Journal of Clinical Oncology. 35(6_suppl). 267–267. 2 indexed citations
7.
Romero-Laorden, Nuria, J.M. Piulats Rodriguez, Ángela del Pozo, et al.. (2017). PROREPAIR-B: A prospective cohort study of DNA repair defects in metastatic castration resistant prostate cancer (mCRPC). Annals of Oncology. 28. v619–v619. 6 indexed citations
8.
Harshman, Lauren C., John Logue, Cora N. Sternberg, et al.. (2017). First interim results of the radium-223 (Ra-223) REASSURE observational study: Analysis of patient (Pt) characteristics and safety by use of abiraterone and/or enzalutamide (Abi/Enza). Annals of Oncology. 28. v279–v280. 4 indexed citations
9.
Puente, Javier, Aranzazu González del Alba, Núria Sala, et al.. (2016). Novel agents’ sequencing following first-line docetaxel in mCRPC patients: CAPRO study.. Journal of Clinical Oncology. 34(2_suppl). 229–229. 1 indexed citations
10.
Virizuela, Juan Antonio, Yolanda Escobar, Javier Cassinello, & Pablo Borrega. (2012). Treatment of cancer pain: Spanish Society of Medical Oncology (SEOM) recommendations for clinical practice. Clinical & Translational Oncology. 14(7). 499–504. 31 indexed citations
11.
Salvador, J., Joan Albanell, Agustín Barnadas, et al.. (2012). Pilot study on workload estimate in breast cancer, lung cancer and colorectal cancer in a Medical Oncology Service at Valme hospital. Clinical & Translational Oncology. 14(11). 820–826. 1 indexed citations
12.
Gámez‐Pozo, Angelo, Luis Antón-Aparicio, Pablo Borrega, et al.. (2012). MicroRNA Expression Profiling of Peripheral Blood Samples Predicts Resistance to First-line Sunitinib in Advanced Renal Cell Carcinoma Patients. Neoplasia. 14(12). 1144–IN14. 57 indexed citations
13.
Salvador, J., Joan Albanell, Agustín Barnadas, et al.. (2012). Functions and workload of medical oncologists in Spain. Clinical & Translational Oncology. 14(6). 423–429. 6 indexed citations
14.
Feliú, Jaime, Pablo Borrega, Ana León, et al.. (2010). Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology. 67(1). 215–221. 26 indexed citations
15.
González-Santiago, Santiago, Ruth Zárate, Juan de la Haba-Rodríguez, et al.. (2007). CYP2D6*4 polymorphism as blood predictive biomarker of breast cancer relapse in patients receiving adjuvant tamoxifen. Journal of Clinical Oncology. 25(18_suppl). 590–590. 13 indexed citations
16.
Borrega, Pablo, et al.. (2004). Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer. Urologic Oncology Seminars and Original Investigations. 22(1). 32–35. 13 indexed citations
17.
Espinosa, Enrique, Serafín Morales, Pablo Borrega, et al.. (2004). Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer. Cancer Chemotherapy and Pharmacology. 54(6). 546–552. 14 indexed citations
18.
Reina, Juan José, Jorge Aparicio, J. Salvador, et al.. (2003). A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology. 52(4). 339–345. 1 indexed citations
19.
Feliú, Jaime, Pablo Borrega, P. Escudero, et al.. (2002). Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas. Annals of Oncology. 13(11). 1756–1762. 27 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Samira El Bouazzaoui Breakdown of academic impact, for papers by Paula Jiménez Fonseca Breakdown of academic impact, for papers by Dan Moldoveanu Breakdown of academic impact, for papers by Fiona Langlands Breakdown of academic impact, for papers by Nur Sabrina Sapari Breakdown of academic impact, for papers by Natalie Reizine Breakdown of academic impact, for papers by Zafer Cantürk Breakdown of academic impact, for papers by Krystyna Reczko Breakdown of academic impact, for papers by Shubao Wang Breakdown of academic impact, for papers by J. R. J. Elbers
Rankless by CCL
2026